Étiquette : Ibogaine

The tripping point : The potential role of psychedelic-assisted therapy in the response to the opioid crisis, Elena Argento et al., 2018

The tripping point : The potential role of psychedelic-assisted therapy in the response to the opioid crisis Elena Argento, Kenneth W. Tupper, M. Eugenia Socias International Journal of Drug Policy, 2019,  66, 80–81 https://doi.org/10.1016/j.drugpo.2018.11.006 0955-3959/ © 2018 Elsevier B.V. All rights reserved A B S T R A C T The increasing contamination of the drug supply with illicitly manufactured fentanyl and related analogs in North America has resulted in the most severe drug-overdose crisis in history. Available pharmaco-therapy options for the treatment of opioid use disorder have had limited success in curbing the current crisis, and a growing body of evidence highlights the need for [...]

Lire la suite

Ibogaine and Subjective Experience: Transformative States and Psychopharmacotherapy in the Treatment of Opioid Use Disorder, Thomas K. Brown et al., 2019

Ibogaine and Subjective Experience : Transformative States and Psychopharmacotherapy in the Treatment of Opioid Use Disorder Thomas K. Brown, PhDa, Geoff E. Noller, PhDb, and Julie O. Denenberg, MAc Journal of Psychoactive Drugs, 2019 https://doi.org/10.1080/02791072.2019.1598603 ABSTRACT This article examines the therapeutic potential of ibogaine, a powerful oneiric alkaloid derived from Tabernanthe iboga, through exploring the subjective experiences of 44 participants from two observational treatment studies for opioid use disorder. Following treatment with ibogaine HCl, the participants (Mexico, n = 30; New Zealand, n = 14) completed the States of Consciousness Questionnaire (SCQ) to quantify the magnitude of their psychotropic experience. Participants were asked to provide [...]

Lire la suite

A phenomenological analysis of the subjective experience elicited by ibogaine in the context of a drug dependence treatment, Eduardo Ekman SCHENBERG et al., 2017

A phenomenological analysis of the subjective experience elicited by ibogaine in the context of a drug dependence treatment EDUARDO EKMAN SCHENBERG, MARIA ANGÉLICA DE CASTRO COMIS, JOÃO FELIPE MOREL ALEXANDRE, LUÍS FERNANDO TÓFOLI, BRUNO DANIEL RASMUSSEN CHAVES, DARTIU XAVIER DA SILVEIRA Journal of Psychedelic Studies, 2017, 1, (2), pp. 74–83 DOI: 10.1556/2054.01.2017.007   Objective : This report documents the phenomenology of the subjective experiences of 22 patients with substancerelated disorders who were involved in a treatment combining cognitive–behavioral therapy and hospital sessions with ibogaine in Brazil. Methods: Participants underwent a one-to-one semi structured interview exploring the subjective effects of ibogaine. We employed interpretative phenomenological analysis [...]

Lire la suite

Treating drug dependence with the aid of ibogaine: A qualitative study, Eduardo EKMAN SCHENBERG et al., 2017

Treating drug dependence with the aid of ibogaine: A qualitative study EDUARDO EKMAN SCHENBERG, MARIA ANGÉLICA DE CASTRO COMIS, JOÃO FELIPE MOREL ALEXANDRE, BRUNO DANIEL RASMUSSEN CHAVES, LUÍS FERNANDO TO´ FOLI and DARTIU XAVIER DA SILVEIRA Journal of Psychedelic Studies, 2017, 1, (1), pp. 10–19 DOI: 10.1556/2054.01.2016.002   Background : Substance use disorders are important contributors to the global burden of disease, but current treatments are not associated with high rates of recovery. The lack of approved and effective treatments is acutely problematic for psychostimulants like cocaine and crack cocaine. One promising alternative in the treatment of drug dependence in general and psychostimulants in particular [...]

Lire la suite

The antiaddictive effects of ibogaine: A systematic literature review of human studies, Rafael G. DOS SANTOS et al., 2017

The antiaddictive effects of ibogaine : A systematic literature review of human studies Rafael G. DOS SANTOS, José Carlos BOUSO and Jaime E. C. HALLAK Journal of Psychedelic Studies, 2017, 1, (1), pp. 20–28 DOI: 10.1556/2054.01.2016.001   Background and aims : Ibogaine is a naturally occurring hallucinogenic alkaloid with a therapeutic potential for reducing drug craving and withdrawal. To the best of our knowledge, no systematic review was previously performed assessing these effects. Thus, we conducted a systematic literature review of human studies assessing the antiaddictive effects of ibogaine. Methods : Papers published up to July 2, 2016 were included from PubMed, LILACS, and SciELO databases [...]

Lire la suite

Detoxification from methadone using low, repeated, and increasing doses of ibogaine : A case report, Clare WILKINS et al., 2017

Detoxification from methadone using low, repeated, and increasing doses of ibogaine : A case report CLARE WILKINS, RAFAEL G. DOS SANTOS, JORDI SOLÁ, MARC AIXALÁ, PEP CURA, ESTEFANÍA MORENO, MIGUEL ÁNGEL ALCÁZAR-CÓRCOLES, JAIME E. C. HALLAK and JOSÉ CARLOS BOUSO Journal of Psychedelic Studies,  2017, 1, (1), pp. 29–34 DOI: 10.1556/2054.01.2017.005   Background and aims : Ibogaine is a natural alkaloid that has been used in the last decades as an adjuvant for the treatment of opiate withdrawal. Despite the beneficial results suggested by animal studies and case series, there is a lack of clinical trials to assess the safety and efficacy of ibogaine. Moreover, [...]

Lire la suite

Current perspectives on psychedelic therapy : use of serotonergic hallucinogens in clinical interventions, Albert Garcia-Romeu and William A. Richards, 2018

Current perspectives on psychedelic therapy : use of serotonergic hallucinogens in clinical interventions Albert Garcia-Romeu and William A. Richards Department of Psychiatry & Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA INTERNATIONAL REVIEW OF PSYCHIATRY, 2018 https://doi.org/10.1080/09540261.2018.1486289   ABSTRACT Humans have used serotonergic hallucinogens (i.e. psychedelics) for spiritual, ceremonial, and recreational purposes for thousands of years, but their administration as part of a structured therapeutic intervention is still a relatively novel practice within Western medical and psychological frameworks. In the mid-20th century, considerable advances were made in developing therapeutic approaches integrating administration of low (psycholytic) and high (psychedelic) doses of serotonergic hallucinogens for treatment [...]

Lire la suite

A Contemporary History of Ibogaine in the United States and Europe, Kenneth R. Alper et al., 2001

A Contemporary History of Ibogaine in the United States and Europe THE ALKALOIDS, 2001, Vol.56, Chapitre 14 Copyright © 2001 by Academic Press 0099-9598/01 Kenneth R. Alper, Dana Beal & Charles D. Kaplan   I. Introduction In 1995, Dr. Curtis Wright, then the U.S. Food and Drug Administration (FDA) ibogaine project officer, wrote “What’s clear is that a significant portion of the public we serve believes the drug merits investigation” (1). Wright’s statement intimates a relationship of public opinion to regulatory scientific policy. The statement was made at a time when the FDA, partly in response to highly motivated and organized public advocacy, was modifying its drug [...]

Lire la suite